Prakt. lékáren. 2016; 12(1): 3
Prakt. lékáren. 2016; 12(1): 6-11
The author presents an overview of the current options of immunomodulatory therapy in routine clinical practice. They are divided into products that are used primarily for anti-inflammatory therapy, immunosubstitution and immunostimulation. Also addressed is the current status of OTC products for „stimulation of immunity“ from the perspective of evidence-based medicine.
Prakt. lékáren. 2016; 12(1): 12-15 | DOI: 10.36290/lek.2016.003
This article reviews current possibilities of topical therapy, phototerapy and systemic therapy, including their indications and contraindications. Except that the article explains necessity of the observance of a healthy lifestyle.
Prakt. lékáren. 2016; 12(1): 16-17 | DOI: 10.36290/lek.2016.004
The article presents clear information on the topic of ADHD, or hyperkinetic conduct disorder and attention disorder, DSM–V, ICD–10. The fundamental condition is attention disorder that is determined biologically (genetically or perinatally). These aetiological factors cause a relatively precisely defined developmental change in the CNS that mainly involves the prefrontal cortex and basal ganglia, is accompanied by deficiency of the dopamine and noradrenaline neurotransmitters, and this deficiency is very successfully managed by administering stimulants or atomoxetine. The developmental issues are defined by various trajectories...
Prakt. lékáren. 2016; 12(1): 18-25 | DOI: 10.36290/lek.2016.005
Glaucoma is a chronic, progressive and non-reversible optic neuropathy, associated with an increase in intraocular pressure which involves loss of retinal ganglion cells and their axons which form the optic nerve. Clinically it manifests characteristic visual field defects adequate distribution of nerve fibers. Glaucoma can be divided according to the etiopathogenesis of primary and secondary glaucoma. In this article, we mention glaucoma generally, primary glaucoma, acute angle-closure glaucoma and then diagnosis and therapy of glaucoma generally.
Prakt. lékáren. 2016; 12(1): 30-32 | DOI: 10.36290/lek.2016.007
This article builds on the previous part of the number 5 (volume 10, 2014) and deals with the evaluation of the risks of common medicinal plants. Patients often do not realize the risks and believe that the effect of herbal drugs multiply by increasing the dosage. There can be achieved a toxic level of some constituent of medicinal plant by this way. The second part of the text includes toxic effects of plants used as medicines: ginkgo, tea tree, senna and ginseng.
Prakt. lékáren. 2016; 12(1): 26-28 | DOI: 10.36290/lek.2016.006
This article deals with budesonide, a new pharmaceutical substance for extemporaneus preparation. Thanks to magistraliter preparation we have new possibility of treatment eosinophilic esophagitis by an extemporaneously prepared highly viscous budesonide suspension. The results of the paper evaluate stability and safety profile of this suspension.
Prakt. lékáren. 2016; 12(1): 11
Prakt. lékáren. 2016; 12(1): 33-36 | DOI: 10.36290/lek.2016.008
Upper respiratory tract infections are common, especially during the autumn and winter season. The human organism is during this period susceptible to bacterial or viral pathogens. The most common symptoms are cough, runny nose, fever and sore throat. Acute course of the difficulties usually brings patients to a pharmacy, where they expect to get appropriate recommendations to the suppression of symptoms. There are given therapeutic options in the text that can affect typical symptoms of upper respiratory tract infection and potential risks associated with the use of drugs.
Prakt. lékáren. 2016; 12(1): 37-38